OTCMKTS:ATTBF - Abattis Bioceuticals Stock Price, News, & Analysis

$0.0293
0.00 (0.00 %)
(As of 07/17/2019 04:00 PM ET)
Today's Range
$0.0280
Now: $0.0293
$0.03
50-Day Range
$0.0276
MA: $0.03
$0.0385
52-Week Range
$0.0170
Now: $0.0293
$0.1919
Volume103,095 shs
Average Volume562,756 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abattis Bioceuticals Corp., a biotechnology company, researches, develops, licenses, and markets ingredients and formulas for use in the biopharma, nutraceutical, cosmetic, and animal nutrition markets in Canada. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and marketing services. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ATTBF
CUSIPN/A
CIKN/A
Phone604-674-8232

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ATTBF News and Ratings via Email

Sign-up to receive the latest news and ratings for ATTBF and its competitors with MarketBeat's FREE daily newsletter.

Abattis Bioceuticals (OTCMKTS:ATTBF) Frequently Asked Questions

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the OTCMKTS under the ticker symbol "ATTBF."

Has Abattis Bioceuticals been receiving favorable news coverage?

Media coverage about ATTBF stock has trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Abattis Bioceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Abattis Bioceuticals.

Who are some of Abattis Bioceuticals' key competitors?

What other stocks do shareholders of Abattis Bioceuticals own?

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the folowing people:
  • Mr. Robert Abenante, Pres, CEO & Director
  • Mr. Douglas J. Sorocco LLB, Advisor (Age 48)
  • Mr. Guy P. Dancosse, Advisor (Age 75)
  • Mr. Francesco Paolini, CFO & Director
  • Mr. Patrick Mitchell, Chief Operating Officer

How do I buy shares of Abattis Bioceuticals?

Shares of ATTBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abattis Bioceuticals' stock price today?

One share of ATTBF stock can currently be purchased for approximately $0.0293.

What is Abattis Bioceuticals' official website?

The official website for Abattis Bioceuticals is http://www.abattis.com/.

How can I contact Abattis Bioceuticals?

The company can be reached via phone at 604-674-8232.


MarketBeat Community Rating for Abattis Bioceuticals (OTCMKTS ATTBF)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  50
MarketBeat's community ratings are surveys of what our community members think about Abattis Bioceuticals and other stocks. Vote "Outperform" if you believe ATTBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATTBF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel